Funding

The information on this page about projects and other funding data may not be exhaustive for reasons of confidentiality and intellectual and industrial property protection. If you need more complete information, please contact the institution.

75 results

Total amount: €24,486,063.00
data available since 2018

2026

  1. PREDOC FUND RAMON ARECES 2025 Raquel Iriarte (N.M.)

    €148,000.00

  2. Advancing immunotherapies for cancer

2025

  1. TERAV+

    €280,720.00

  2. The Immunopeptidome of crosspriming

    €54,970.00

  3. Determination of sPDL1 in serum samples

    €4,355.00

  4. G-Rex® Grant Award

2024

  1. RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming

    €2,411,500.00

  2. Uncovering resistance mechanism to CAR-T cells via deep learning in scRNAseq for improved therapies

    €359,500.00

  3. Combinaciones sinérgicas en inmunoterapia del cáncer de agentes agonistas que interfieren con la inflamación pro-tumoral

    €501,875.00

  4. REVOLUTION: Evolución de ARN estructurales en cáncer de colon para medicina personalizada.

    €221,070.00

  5. Inmunoterapia con células CAR-T frente a antígenos del estroma para el tratamiento de PDAC

    €235,950.00

  6. NON-BINDING TERM SHEETFOR PoC NETWORK AGREEMENT

2023

  1. Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC

    €100,000.00

  2. Coestimulación condicional a través de 4-1BB que explota el Crosspriming en cáncer CONDICOS

    €184,763.00

  3. Plataforma para la Identificación de TCR Específicos de Antígenos Tumorales para la Inmunoterapia de Tumores Sólidos (PITAGORAS)

    €474,228.00

  4. Ensayo Clínico de fase I/II para el tratamiento de la enfermedad del injerto contra el huésped con una nueva generación de células estromales mesenquimales que expresan ectópicamente CXCR4 e IL10

    €1,207,250.00

  5. Células dendríticas decross-priming como vacunas en una estrategia de inmunoterapia para cánceres renales y de urotelio.

    €1,007,600.00

  6. IMMUTOL - Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases

    €900,000.00

  7. Translational Research for BI 765179 CD137/FAP Agonist

    €625,125.00

  8. Expression&significance of PD1&LAG3 in selected tumor types

    €175,000.00

The information on this page about projects and other funding data may not be exhaustive for reasons of confidentiality and intellectual and industrial property protection. If you need more complete information, please contact the institution.